Cancer cell pathways

Cancer cell pathways encompass the intricate networks of biochemical signaling and metabolic processes that are aberrantly regulated to drive the initiation, progression, and survival of malignant tumors. These pathways, which include the PI3K/AKT/mTOR, MAPK/ERK, and Wnt/beta-catenin cascades, are often hijacked by genetic mutations or epigenetic alterations to promote the 'hallmarks of cancer,' such as uncontrolled proliferation, resistance to cell death, and induced angiogenesis (Hanahan & Weinberg, Cell, 2011; AACR Journals, 2022). While these pathways are the primary focus of modern oncology, 'Cancer cell pathways' itself is a broad descriptive category rather than a discrete molecular target; instead, it comprises numerous individual proteins, enzymes, and receptors that serve as specific therapeutic targets for small molecule inhibitors and monoclonal antibodies (ASCO Publications, 2013; Liv Hospital, 2026). Targeted therapies, such as tyrosine kinase inhibitors and immune checkpoint blockers, aim to disrupt these specific nodes within the larger network to restore homeostatic control or induce tumor cell death (Dr. Ruchir Tandon, 2024; Massive Bio, 2026). The identification of specific actionable mutations within these pathways has paved the way for precision medicine, allowing for treatments tailored to the molecular profile of an individual's tumor (Liv Hospital, 2026). Understanding the complexity and redundancy of these pathways is essential for developing effective combination therapies and overcoming the challenges of therapeutic resistance (NIH, 2021; Frontiers in Oncology, 2020).

Other names

Oncogenic signaling pathwaysTumorigenic pathwaysCancer signaling networksHallmarks of cancer pathwaysPathways in cancer

Inhibition or modulation of specific signaling cascades, enzymes, or receptors that drive the hallmarks of cancer, such as sustained proliferation and evasion of apoptosis.